Integra LifeSciences
This article was originally published in The Gray Sheet
Executive Summary
Eight person jury finds that Merck KGaA willfully infringed and induced infringement of four patents licensed to Integra, awarding the Plainsboro, New Jersey firm $15 mil. in damages in California federal court March 17. The patents in question, which Integra licensed from the Burnham Institute of San Diego (No. 4,792,525, No. 4,879,237, No. 5,659,997 and No. 4,789,734) relate to technology involving peptides containing arginine-glycine-aspartic acid sequences or related cell surface receptors. Integra originally filed the suit in 1996. Merck is expected to appeal the decision
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.